• Hansa Biopharma filed a confidential draft Form F-1 with the SEC for a potential U.S. listing of American depositary shares.
• Planned Nasdaq Global Market ticker: HNSA; Stockholm listing would remain in place.
• Offering size, ADS-to-share ratio, timing, and price range have not been set.
• Transaction also contemplates a parallel private placement of shares in Europe to selected qualified investors.
• Completion hinges on SEC and Nasdaq review processes, market conditions, and investor demand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief on August 21, 2026, and is solely responsible for the information contained therein.